Our investment in UCB
UCB focuses on discovering and developing innovative treatments to transform the lives of patients suffering from serious illnesses that affect their immune system or their central nervous system.
The ambition of UCB is to give those suffering from serious illnesses the freedom to live their lives as well as possible, protected from the uncertainties caused by diseases. All the staff at UCB aim to work on a sustainable basis for their company, their colleagues, the communities around them and the planet.
Key figures of the UCB group (listed on Euronext Brussels)
5.25
€ b turnover
(2022 : € 5.52 b)
31%
R&D / turnover ratio
(2022 : 30%)
10
Molecules in clinical pipeline
(2022 : 9)
9,083
UCB staff members worldwide
(2022 : 8,700)
25,7%
Adjusted EBITDA / turnover ratio
(2022 : 22.8%)
3.2
m patients have access to the solutions provided by UCB
-55%
Reduction in CO21 emissions
(2022 : -58%)
ESG ratings2
Sustainalytics : 17,3
MSCI : AA
ISS : C+
1CO2 emissions controlled directly by UCB compared with the reference year 2015
2Ratings in February 2024
